FORT WORTH, Texas, May 19, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions announced the publication of an interview of its President Deborah Jenkins Hutchinson by CEOCFOInterviews.com, a weekly web publication consisting of interviews with CEOs and CFOs of publicly traded growth companies.
Topics within the interview, conducted by Lynn Fosse, Senior Editor, CEOCFOInterviews.com include why Ms. Jenkins Hutchinson joined the Company, how and why the Company's FDA approved flagship product, CellerateRX®, has become a primary treatment for all types of wounds (except 3rd degree burns) and the reasons why the investment community is beginning to take notice of the public company's common stock (WNDM: OTCQB).
In the interview, the Wound Management President summarizes the Company's progress by stating, "Wound Management Technologies is growing and hitting its milestones. It will be cash flow positive, and it will be profitable. We are doing what we said we were going to do and we believe Wound Management Technologies is going to emerge into quite a strong company."
The interview can be accessed at either;
http://ceocfointerviews.com/interviews/WNDM-WoundManagement11.htm or within the newly reconfigured Wound Management Technologies website http://www.wmgtech.com. For more information on the Company and/or to be added to the Company's investor email list, please call our investor relations office at 917-974-9872 or enter your name and email address in the "Get WNDM News" area at the top of the Company's website.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved